Rebion

What Rebion does

Rebion is a Boston-based, privately held medical device company founded in 2009 that has developed a proprietary retinal scanning platform called Neural Performance Scanning (NPS). NPS quantifies bilateral fixation and saccadic movement to measure the neurophysiologic mechanism of the optic nerve and brain continuum, enabling direct detection of impairments such as micro-strabismus and amblyopia in pediatric vision screening rather than merely estimating risk factors. The company's commercial product is Blinq, an FDA-cleared portable neural performance scanner that conducts a 3-second scan of the fovea and reports up to 100% sensitivity and over 90% specificity in clinical evaluations. A second product, Traq, applies the same NPS technology to measure visual tracking impairments for clinical research and is currently investigational, not available for sale in the United States.

Rebion monetizes through hardware sales of FDA-cleared scanning devices to healthcare providers, schools, and community screening programs, operating an enterprise field sales motion targeting doctors, clinical staff, school administrators, and community screeners. The company has raised approximately $11.08 million across five disclosed funding rounds from 2011 through 2019, including an NIH-funded clinical study that validated Blinq's accuracy in detecting amblyopia. The customer base is segmented across healthcare institutions, educational settings, community health organizations, and parents/caregivers, with multi-stakeholder content on the company website tailored to each segment.

The company is small, with 1-10 employees, and operates from 100 Cambridge Street in Boston. In 2024, Rebion appointed Mark Maire as CEO to lead the next phase of commercialization. Pricing is not publicly disclosed; sales inquiries are handled via a dedicated phone line. The firm's regulatory position is its principal commercial asset, as Blinq is described as the only FDA-cleared portable neural performance scanner for detecting micro-strabismus and amblyopia, providing a defensible regulatory moat in its specific screening indication.

Name

Rebion

Legal name

Rebion

Website

https://rebiscan.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Rebion is a Boston-based medical device company that sells Blinq, an FDA-cleared portable neural performance scanner using proprietary retinal scanning to directly detect micro-strabismus and amblyopia in children, serving doctors, schools, and community screening programs.

Ownership category

akta.pro rank

Product category

Medical Devices - Pediatric Vision Screening

NAICS

Ophthalmic Goods Manufacturing (339115), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment) (HLAHAJAM)

akta.pro secondary industries

Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC), Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)

Keywords

• Pediatric vision screening
• Retinal scanning devices
• Medical imaging devices
• Neural performance scanning
• Amblyopia detection

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of FDA-cleared neural performance scanning devices (Blinq) to healthcare providers, schools, and clinical institutions. Hardware-based revenue model with point-of-care portable devices.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Rebion manufactures and sells FDA-cleared portable neural performance scanners (Blinq) that directly detect micro-strabismus and amblyopia (lazy eye) in children through a 3-second retinal scan of the fovea. The company's proprietary Neural Performance Scanning (NPS) technology quantifies bilateral fixation and saccadic movement to measure neurophysiologic signals from the optic nerve/brain continuum, enabling early, objective pediatric vision screening in clinical, school, and community settings.

Product overview

Rebion offers a portfolio of point-of-care medical devices based on its proprietary Neural Performance Scanning (NPS) technology. The core product is Blinq, an FDA-cleared portable neural performance scanner designed for early vision screening. Traq is an investigational research tool that applies the same NPS technology to visual tracking assessment. Both products leverage retinal scanning to detect neurological and visual processing impairments, with Blinq targeting pediatric vision screening (amblyopia and micro-strabismus detection) while Traq focuses on clinical research applications.

Differentiator

Problem solved

Functional benefit

Brands

• Blinq: FDA-cleared portable neural performance scanner that directly detects micro-strabismus and amblyopia through a 3-second scan of the fovea, achieving up to 100% sensitivity and over 90% specificity.
• Traq

Products and services

• Blinq Vision Scanner

Quantifiable outcome

• Up to 100% sensitivity in clinical evaluations for detecting amblyopia and strabismus
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Plusoptix: Plusoptix manufactures portable pediatric vision screening devices (autorefractors/photo-screeners) used by pediatricians, schools, and vision screening programs. It is a direct competitor to Blinq in the same pediatric vision screening point-of-care category, although Rebion's NPS approach is mechanistic-different.
• LKC Technologies: LKC Technologies develops specialized electrophysiology and visual function testing devices (e.g., RETeval, Ganzfeld ERG), serving ophthalmology and vision research end markets. It is comparable to Rebion in ophthalmic diagnostic instrumentation and clinical research applications of visual function measurement.
• GoCheck Kids: GoCheck Kids provides a smartphone-based pediatric vision screening platform used by pediatricians and schools. It targets the same early-detection use case as Blinq (amblyopia risk-factor screening) but via a software/hardware-as-a-service model rather than dedicated hardware.
• iScreen Vision: iScreen Vision (now part of SLP Healthcare) sells portable pediatric vision screening devices used in pediatric offices and school programs, directly competing with Rebion's Blinq in the same screening workflow and customer base.

Emerging players

• RightEye: RightEye provides eye-tracking-based vision and neurological assessment tools, including concussion and functional vision screening. It is comparable as an emerging player applying objective ocular measurement (eye tracking) to neurological and pediatric screening use cases that overlap with Rebion's NPS-based Traq product direction.
• Konan Medical: Konan Medical develops specialty ophthalmic diagnostic devices (e.g., pupillometry, functional vision testing) used in clinical and research settings. It is comparable as a focused ophthalmic diagnostic device peer with adjacent functional vision testing capabilities.

Broad incumbents

• Natus Medical: Natus Medical is a broad incumbent in neurological and sensory diagnostic devices, including visual/neurological screening. It is comparable as a larger strategic that could pursue adjacent point-of-care neurological screening applications similar to Rebion's NPS platform.
• Welch Allyn (Hillrom / Baxter): Welch Allyn (now part of Baxter via Hillrom) markets the Spot Vision Screener, a widely deployed pediatric photo-screening device. It is a broad incumbent with overlapping capabilities in pediatric vision screening, supported by a much larger distribution and capital base.
• Topcon Healthcare: Topcon Healthcare is a major ophthalmic device and diagnostic imaging company whose portfolio overlaps with retinal scanning and ocular diagnostic instrumentation. It represents a broad incumbent comparable to Rebion in ophthalmic imaging/diagnostics.
• Carl Zeiss Meditec: Carl Zeiss Meditec is a global ophthalmic diagnostics and surgical device leader, including ocular imaging and functional vision testing technologies. It is a broad incumbent with overlapping R&D focus areas around retinal imaging and visual function testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/rebiscan
• Facebookfacebook.com/rebiscan
• LinkedInlinkedin.com/company/1254401

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rebion